Genetic polymorphisms influencing therapy and susceptibility to rejection in organ allograft recipients

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Francesca PoliMario Scalamogna

Abstract

Solid organ transplantation during the past 30 years has developed from an experimental procedure into routine clinical practice. The current repertoire of immunosuppressive agents has made a major contribution to transplant survival; however, problems in different areas still need to be overcome. Several gene polymorphisms are supposed to influence immunosuppressive therapy and susceptibility to rejection. Therefore, a priority of transplant biologists is to estimate individual patient risk and to characterise the genetic profile of patients in need of a transplant in order to optimise the use of a scarce resource such as organs from cadaver donors, and to avoid serious drug-induced adverse effects. Polymorphisms in genes encoding tumour necrosis factor-alpha (TNFalpha), interleukin (IL)-6, IL-10, interferon-gamma (IFNgamma), transforming growth factor-beta (TGFbeta) and thiopurine S-methyltransferase (TPMT) can have significant effects on an individual's risk of rejection, as well as their ability to tolerate immunosuppressive therapy. Genotyping of known polymorphisms in these genes may in the future contribute to our ability to individualise immunosuppressive therapy in organ transplant recipients.

References

Oct 23, 1992·Science·T KishimotoT Taga
Jan 1, 1991·Annual Review of Medicine·S Hunt, M Billingham
Jul 1, 1991·The Journal of Experimental Medicine·A E GoldfeldC Doyle
Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A E GoldfeldT Maniatis
Jan 1, 1989·Annual Review of Immunology·B Beutler, A Cerami
Jul 1, 1989·The Journal of Experimental Medicine·J S EconomouD L Morton
Aug 1, 1989·Clinical Pharmacology and Therapeutics·L LennardR M Weinshilboum
Nov 1, 1995·The Journal of Experimental Medicine·M CabreraJ M Blackwell
Oct 1, 1994·Current Opinion in Immunology·H Azuma, N L Tilney
Jan 1, 1994·European Journal of Immunology·A G WilsonG W Duff
Feb 13, 1993·Lancet·E S Siris
Jan 1, 1994·Clinical Pharmacology and Therapeutics·H L McLeodW E Evans
May 1, 1993·Transplantation·G P BasadonnaJ S Najarian
Feb 1, 1997·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·D M TurnerI V Hutchinson
Feb 3, 1997·The Journal of Experimental Medicine·M RincónR A Flavell
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·A G WilsonG W Duff
Apr 1, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·J WaiserH H Neumayer
Jan 1, 1997·Annual Review of Immunology·U BoehmJ C Howard
Apr 1, 1997·Molecular Immunology·K M KroegerL J Abraham
Oct 6, 1997·Transplantation·D TurnerI V Hutchinson
Nov 22, 1997·Current Opinion in Immunology·C G Orosz, R P Pelletier
Jun 12, 1998·The New England Journal of Medicine·J A Fishman, R H Rubin
Oct 23, 1998·British Journal of Rheumatology·C L Verweij, T W Huizinga
Dec 29, 1998·Transplantation Proceedings·P Häyry
Mar 9, 1999·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·V PravicaI V Hutchinson
Mar 20, 1999·Transplantation Proceedings·I V HutchinsonP Sinnott
Jul 20, 1999·Kidney International·D SankaranI V Hutchinson
Aug 24, 1999·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·A N AbdallahA Iron

❮ Previous
Next ❯

Citations

Jan 31, 2006·Tissue Antigens·L A MarínM R Alvarez-López

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.